{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T13:40:09Z","timestamp":1777124409788,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Youth Key Project of Wannan Medical College","award":["No. WK2021ZF08, No. WK2023ZZD34"],"award-info":[{"award-number":["No. WK2021ZF08, No. WK2023ZZD34"]}]},{"DOI":"10.13039\/100015801","name":"Anhui Provincial Quality Engineering Project","doi-asserted-by":"publisher","award":["No. 2023jyxm1241"],"award-info":[{"award-number":["No. 2023jyxm1241"]}],"id":[{"id":"10.13039\/100015801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lung adenocarcinoma (LUAD) is a common subtype of non-small cell lung cancer (NSCLC) with a poor prognosis. To identify novel biomarkers and understand the underlying mechanisms in LUAD, we conducted a comprehensive analysis using single-cell and bulk RNA sequencing data. Our study focused on LAD1, a basement membrane filament protein that has been implicated in tumorigenesis in various cancers. We analyzed scRNA-seq data from 10 LUAD patients and identified nine cell subgroups, with LAD1 specifically expressed in cancer cells. Further analysis revealed significant correlations between LAD1 and genes associated with LUAD progression, including SFTPB, S100A6, CEACAM6, KRT19, S100A10, ANXA2, S100A11, and CAPN2. We investigated the effects of altered LAD1 expression on differentially expressed genes (DEGs), biological processes, and signaling pathways. Furthermore, we collected cancer tissue and corresponding adjacent tissue samples from 36 LUAD patients, used immunohistochemical staining to detect LAD1 expression, and analyzed its correlation with clinicopathological characteristics. We knocked down the expression of LAD1 in A549 cells using siRNA, and detected changes in LUAD cell migration and invasion ability through scratch healing assay and Transwell assay. Our results indicated diverse effects of LAD1 at both the single-cell and whole tumor levels, with a convergence on processes associated with tumor progression. In lung adenocarcinoma tissues, LAD1 was significantly upregulated, particularly in the cancer cell subgroup within tumors. Immunohistochemical results showed that LAD1 was highly expressed in LUAD, and knocking down LAD1 could inhibit LUAD cell migration and invasion. Pan-cancer analyses demonstrated LAD1 as an independent prognostic factor for overall survival in LUAD. Moreover, we developed a nomogram model incorporating LAD1 expression and clinical parameters, which demonstrated good predictive performance. The high expression of LAD1 in cancer cells, its associations with LUAD-related genes, and its links to biological processes and pathways suggest its potential biological relevance and that it merits further investigation. Overall, this study provides insights into LUAD and supports LAD1 as a gene worthy of further investigation.<\/jats:p>","DOI":"10.1038\/s41598-025-33277-z","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T14:06:07Z","timestamp":1766325967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the expression and prognostic roles of LAD1 in lung adenocarcinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Sufen","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banghong","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"issue":"3","key":"33277_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"Cancer J. Clin."},{"issue":"8","key":"33277_CR2","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.jtho.2018.05.014","volume":"13","author":"HA Hamann","year":"2018","unstructured":"Hamann, H. A., Ver Hoeve, E. S., Carter-Harris, L., Studts, J. L. & Ostroff, J. S. Multilevel opportunities to address lung cancer stigma across the cancer control continuum. J. Thorac. Oncol. 13 (8), 1062\u20131075 (2018).","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"33277_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13046-020-01772-y","volume":"39","author":"CC Hao","year":"2020","unstructured":"Hao, C. C. et al. Up-regulation of VANGL1 by IGF2BPs and miR-29b-3p attenuates the detrimental effect of irradiation on lung adenocarcinoma. J. Exp. Clin. Cancer Res. 39 (1), 256 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7689","key":"33277_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553 (7689), 446\u2013454 (2018).","journal-title":"Nature"},{"issue":"1","key":"33277_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12957-022-02727-7","volume":"20","author":"F Wang","year":"2022","unstructured":"Wang, F., Lin, H., Su, Q. & Li, C. Cuproptosis-related LncRNA predict prognosis and immune response of lung adenocarcinoma. World J. Surg. Oncol. 20 (1), 275 (2022).","journal-title":"World J. Surg. Oncol."},{"issue":"10","key":"33277_CR6","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1007\/s00262-022-03143-2","volume":"71","author":"P Song","year":"2022","unstructured":"Song, P. et al. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma. Cancer Immunol. Immunother. 71 (10), 2341\u20132354 (2022).","journal-title":"Cancer Immunol. Immunother"},{"key":"33277_CR7","doi-asserted-by":"publisher","first-page":"749241","DOI":"10.3389\/fimmu.2022.749241","volume":"13","author":"X Li","year":"2022","unstructured":"Li, X. et al. The comprehensive analysis identified an autophagy signature for the prognosis and the immunotherapy efficiency prediction in lung adenocarcinoma. Front. Immunol. 13, 749241 (2022).","journal-title":"Front. Immunol."},{"issue":"5","key":"33277_CR8","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/molbev\/msv007","volume":"32","author":"JC Teixeira","year":"2015","unstructured":"Teixeira, J. C. et al. Long-Term balancing selection in LAD1 maintains a missense Trans-Species polymorphism in Humans, Chimpanzees, and bonobos. Mol. Biol. Evol. 32 (5), 1186\u20131196 (2015).","journal-title":"Mol. Biol. Evol."},{"issue":"3","key":"33277_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1006\/geno.1996.4507","volume":"39","author":"K Motoki","year":"1997","unstructured":"Motoki, K., Megahed, M., LaForgia, S. & Uitto, J. Cloning and chromosomal mapping of mouse ladinin, a novel basement membrane zone component. Genomics 39 (3), 323\u2013330 (1997).","journal-title":"Genomics"},{"issue":"1","key":"33277_CR10","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1186\/s12885-020-07660-0","volume":"20","author":"B Moon","year":"2020","unstructured":"Moon, B. et al. LAD1 expression is associated with the metastatic potential of colorectal cancer cells. BMC Cancer. 20 (1), 1180 (2020).","journal-title":"BMC Cancer"},{"issue":"1","key":"33277_CR11","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1080\/21655979.2021.1968647","volume":"12","author":"J Li","year":"2021","unstructured":"Li, J., Wang, Z. & Tie, C. High expression of ladinin-1 (LAD1) predicts adverse outcomes: a new candidate docetaxel resistance gene for prostatic cancer (PCa). Bioengineered 12 (1), 5749\u20135759 (2021).","journal-title":"Bioengineered"},{"key":"33277_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/scisignal.aan0949","volume":"11","author":"L Roth","year":"2018","unstructured":"Roth, L. et al. SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors. Sci. Signal. 11, 515 (2018).","journal-title":"Sci. Signal."},{"issue":"7403","key":"33277_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486 (7403), 346\u2013352 (2012).","journal-title":"Nature"},{"key":"33277_CR14","doi-asserted-by":"crossref","unstructured":"Chang, C. Y. et al. Ladinin 1 shortens survival via promoting proliferation and enhancing invasiveness in lung adenocarcinoma. Int. J. Mol. Sci. ;24(1). (2022).","DOI":"10.3390\/ijms24010431"},{"key":"33277_CR15","doi-asserted-by":"crossref","unstructured":"Hu, L. et al. The tumorigenic effect of the high expression of Ladinin-1 in lung adenocarcinoma and its potential as a therapeutic target. Molecules ;28(3). (2023).","DOI":"10.3390\/molecules28031103"},{"key":"33277_CR16","doi-asserted-by":"crossref","unstructured":"Yuan, K., Zhang, Y., Yu, Y., Xu, Y. & Xian, S. Anchoring filament protein Ladinin-1 is an immunosuppressive microenvironment and cold tumor correlated prognosticator in lung adenocarcinoma. Biochem. Genet. (2023).","DOI":"10.1007\/s10528-023-10370-4"},{"issue":"9","key":"33277_CR17","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/1759-7714.13558","volume":"11","author":"H Du","year":"2020","unstructured":"Du, H. et al. CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and is regulated by microRNA-146a and microRNA-26a. Thorac. Cancer. 11 (9), 2473\u20132482 (2020).","journal-title":"Thorac. Cancer"},{"key":"33277_CR18","doi-asserted-by":"publisher","first-page":"101402","DOI":"10.1016\/j.tranon.2022.101402","volume":"20","author":"EY Kim","year":"2022","unstructured":"Kim, E. Y., Cha, Y. J., Jeong, S. & Chang, Y. S. Overexpression of CEACAM6 activates Src-FAK signaling and inhibits anoikis, through homophilic interactions in lung adenocarcinomas. Transl Oncol. 20, 101402 (2022).","journal-title":"Transl Oncol."},{"issue":"4","key":"33277_CR19","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1002\/cam4.5221","volume":"12","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. CEACAM6 serves as a biomarker for leptomeningeal metastasis in lung adenocarcinoma. Cancer Med. 12 (4), 4521\u20134529 (2023).","journal-title":"Cancer Med."},{"key":"33277_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.biomaterials.2015.07.012","volume":"67","author":"KP Hong","year":"2015","unstructured":"Hong, K. P. et al. Therapeutic effect of anti CEACAM6 monoclonal antibody against lung adenocarcinoma by enhancing Anoikis sensitivity. Biomaterials 67, 32\u201341 (2015).","journal-title":"Biomaterials"},{"issue":"4","key":"33277_CR21","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.7150\/jca.51179","volume":"12","author":"X Yuan","year":"2021","unstructured":"Yuan, X., Yi, M., Dong, B., Chu, Q. & Wu, K. Prognostic significance of KRT19 in lung squamous cancer. J. Cancer. 12 (4), 1240\u20131248 (2021).","journal-title":"J. Cancer"},{"key":"33277_CR22","doi-asserted-by":"crossref","unstructured":"Wang, W., He, J., Lu, H., Kong, Q. & Lin, S. KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis. Biosci. Rep. ;40(7). (2020).","DOI":"10.1042\/BSR20193468"},{"issue":"36","key":"33277_CR23","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1200\/JCO.2013.50.6105","volume":"31","author":"DD Sin","year":"2013","unstructured":"Sin, D. D. et al. Pro-surfactant protein B as a biomarker for lung cancer prediction. J. Clin. Oncol. 31 (36), 4536\u20134543 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"33277_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/cbf.3639","volume":"39","author":"T Wang","year":"2021","unstructured":"Wang, T., Han, S. & Du, G. S100A6 represses Calu-6 lung cancer cells growth via inhibiting cell proliferation, migration, invasion and enhancing apoptosis. Cell. Biochem. Funct. 39 (6), 771\u2013779 (2021).","journal-title":"Cell. Biochem. Funct."},{"issue":"5","key":"33277_CR25","doi-asserted-by":"publisher","first-page":"e0197402","DOI":"10.1371\/journal.pone.0197402","volume":"13","author":"D Chen","year":"2018","unstructured":"Chen, D., Luo, L., Liang, C. & Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma. PLoS One. 13 (5), e0197402 (2018).","journal-title":"PLoS One"},{"issue":"5","key":"33277_CR26","first-page":"733","volume":"43","author":"H Wang","year":"2023","unstructured":"Wang, H., Sun, Z., Zhao, W. & Geng, B. [S100A10 promotes proliferation and invasion of lung adenocarcinoma cells by activating the Akt-mTOR signaling pathway]. Nan Fang Yi Ke Da Xue Xue Bao. 43 (5), 733\u2013740 (2023).","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"33277_CR27","doi-asserted-by":"publisher","first-page":"4526609","DOI":"10.1155\/2021\/4526609","volume":"2021","author":"Y Ju","year":"2021","unstructured":"Ju, Y., Yuan, B., Wu, W., Zhao, J. & Shi, X. CircRNA ANXA2 promotes lung cancer proliferation and metastasis by upregulating PDPK1 expression. J. Oncol. 2021, 4526609 (2021).","journal-title":"J. Oncol."},{"issue":"1","key":"33277_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.7150\/ijbs.28834","volume":"15","author":"F Xu","year":"2019","unstructured":"Xu, F. et al. Calpain-2 enhances Non-Small cell lung cancer progression and chemoresistance to Paclitaxel via EGFR-pAKT pathway. Int. J. Biol. Sci. 15 (1), 127\u2013137 (2019).","journal-title":"Int. J. Biol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33277-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33277-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33277-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:58:56Z","timestamp":1777121936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33277-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["33277"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33277-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,21]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45124"}}